Dnca Finance Acquires 14,000 Shares of Medtronic PLC $MDT

Dnca Finance boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 17.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,550 shares of the medical technology company’s stock after buying an additional 14,000 shares during the quarter. Dnca Finance’s holdings in Medtronic were worth $8,329,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of MDT. 1248 Management LLC bought a new position in shares of Medtronic in the 1st quarter worth $26,000. Twin Tree Management LP purchased a new position in Medtronic in the first quarter valued at about $29,000. Activest Wealth Management raised its holdings in Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares in the last quarter. GFG Capital LLC purchased a new stake in shares of Medtronic during the second quarter valued at about $36,000. Finally, True Wealth Design LLC lifted its position in shares of Medtronic by 49.8% during the second quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after buying an additional 140 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of MDT opened at $101.39 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The company’s fifty day moving average price is $96.79 and its 200-day moving average price is $92.22. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33. The firm has a market capitalization of $129.99 billion, a PE ratio of 27.33, a price-to-earnings-growth ratio of 2.67 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s dividend payout ratio is currently 76.55%.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Jefferies Financial Group reiterated a “hold” rating and set a $110.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. JPMorgan Chase & Co. raised their price objective on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Leerink Partners set a $120.00 target price on Medtronic and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average price target of $110.44.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.